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Abstract  
Heart failure is one of the commonest diagnoses 
presenting to physicians in the community or hospital 
care. Symptoms are often subjective, with clinicians 
having to rely on clinical assessment and radiological 
imaging to manage these patients. Treatment is often 
symptomatic with no clear therapeutic goals as yet 
identified. To date, there are no objective measures to 
diagnose, predict, prognosticate or guide therapy in 
compensated and decompensated heart failure, which is 
why a novel biomarker guided management approach is 
gaining so much momentum in the clinical community. 
This review encompasses recent data on this new 
approach and details on the potential clinical benefits of 
the most widely studied cardiac biomarkers currently 
available. 
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What is a biomarker?  
The term biomarker was first introduced in 1989 
and was defined as a ‘’measurable and quantifiable 
biological parameter which is used to asses health and 
physiology in a patient in terms of disease risk and 
diagnosis’’. This definition was later amended in 2001 
by a National Institute of Health (NIH) working group as 
an ‘’objectively measured parameter that is an indicator 
of normal biological processes, pathogenic processes or 
as a response to pharmacological therapy’’.1 Ever since 
the concept’s birth, its potential prospects are slowly 
gaining momentum in the medical community. 
 
Biomarkers: The new paradigm in heart failure  
Heart failure (HF) symptoms are often very 
misleading and subjective, particularly if not associated 
with signs of fluid overload. In spite of better resources, 
there are limited tools at the physician’s disposal to 
objectively diagnose and follow up this ever growing 
pathological entity. The genomic changes associated 
with the physiological factors involved, contribute to 
multiple molecular, cellular and interstitial changes.  
These changes occur as a result of chronically activated 
response systems. Signs of cardiac de-compensation 
happen when remodelling is excessive.  
HF is a complex multi-system disorder (Figure 1) 
characterised by abnormalities in cardiac myocytes, 
altered renal function and neurohormonal changes. All 
these act as compensatory mechanisms to maintain 
adequate cardiac output in the presence of cardiac 
insults. Neurohormonal systems (renin-angiotensin 
(RAS), sympathetic (SNS) and arginine-vasopressin 
(AVS) systems) are activated to increase myocardial 
contractility, heart rate, peripheral vasoconstriction and 
promote salt and water retention. When these systems 
fail to compensate, various structural change take place 
in the myocardium. Fluid overload because of worsening 
cardiac output results in myocardial stretch and release 
of natriuretic peptides (NPs). Oxidative stress and 
myocardial injury take place when vascular supply is 
disproportionately low compared to demand. Recurrent 
cell damage up-regulates certain inflammatory and 
remodelling mediators at the point of decompensation. 
Modelling mediators like galectin-3, soluble ST2 
(sST2), matrix metalloproteinases (MMP), tumour 
necrosis factor alpha (TNF-α) and endothelin stimulate a 
number of signal transduction cascades. The consequent 
myocyte hypertrophy, fibroblastic activity and apoptosis, 
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give rise to a vicious cycle of cardiac structural 
remodelling. The capillary versus myocyte mismatch in 
response to these structural changes worsens myocardial 
dysfunction, decreasing cardiac chamber compliance 
and diastolic dysfunction. 
Such insights into the pathophysiology of HF have 
brought about promising advances in the discovery and 
clinical utility of specific cardiac biomarkers. If used 
wisely, cardiac biomarkers can be used as i) prognostic 
predictors (predict onset or worsening of HF), ii) 
objectively diagnose compensated or decompensated 
HF, iii) risk stratify patients, iv) develop new specific 
target therapy (at the biochemical level) or v) as a 
biological tool to guide therapy.2 
Understanding the physiological pathways and 
functions of biomarkers (Figure 1) will help clinicians 
better understand the potential of these biomarkers in the 
clinical field. Whilst most of the available biomarkers 
are still in their infancy in terms of their roles and 
clinical utility in heart failure, NPs, galectin-3, sST2, 
growth differentiation factor-15 (GDF-15) and troponin 
T are showing potential in this field. NPs definitely 
stand out, with the markers most studied and utilised in 
biomarker guided HF management. In the following 
sections, a closer look is taken in the various biomarkers 
available, all of which will be discussed separately in the 
next sections. 
 
 
Figure 1: Pathophysiological pathways of cardiac biomarkers in Heart Failure 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Abbreviations: IL (Interleukins), CRP (C-reactive peptide), TNF-a (Tumour Necrosis Factor alpha), MMPs (Matrix 
Metallo-proteinases), GDF-15 (Growth Differentiation Factor), NPs (Natriuretic Peptides), LDL (Low density 
lipoprotein), RAS (Renin-Angiotensin System) 
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Natriuretic Peptides (NPs) 
NPs including brain natriuretic peptide (BNP), N-
terminal pro-Brain Natriuretic Peptide (NT-proBNP) and 
adrenomedullin (ADM) are peptides released in 
response to myocardial strain (particularly atrial stretch) 
during fluid overload. This is the case in acute 
decompensated HF (ADHF). These peptides work by 
promoting vasodilation, natriuresis and diuresis. Both 
BNP and NT-proBNP are released in their precursor 
form.3 The short half-life and disease dependent 
fluctuant levels make NPs very useful in the 
management of dyspnoeic patients. ADM on the other 
hand, has a very short half-life hence making it a poor 
predictive biomarker. Its precursor MR-proADM has a 
longer half-life, overcoming ADM’s problem in this 
regard.  According to the multicentre BACH trial,4 MR-
proADM was deemed non-inferior to BNP. 
NPs have been extensively studied as objective 
diagnostic markers of HF. A high value in an acutely 
dyspnoeic patient can be used to quantify acute 
decompensated heart failure (ADHF) severity whilst a 
low value (<100pg/mL of BNP) effectively excludes 
ADHF as a differential for acute dyspnoea due to its 
excellent sensitivity (96.98% as per BACH Trial).4 
Whilst high values might possibly reflect ADHF, one 
should adjust levels for renal dysfunction (higher 
baseline) and obesity (lower baseline). Of note, 
natriuretic peptide levels may be relatively low in 
patients presenting with flash pulmonary oedema, often 
because a short time interval precedes the up-regulated 
de-novo peptide synthesis after natriuretic peptide stores 
are acutely depleted.5 
All the NPs are independent predictors of future 
cardiac events and hospitalisations as stated in the Val-
HeFT trial.3 Such markers can be used to help identify 
those at risk patients who would benefit from an earlier 
follow up and tighter risk factor control. 
There is significant potential with the use of 
natriuretic peptides as prognostic markers. The 
IMPROVE-CHF study confirmed the usefulness of these 
peptides (NT-proBNP in particular) in the management 
of the acutely dyspnoeic patient.6 Other studies have 
particularly shown their usefulness as mortality 
predictors with a high BNP associated with a 3-4 fold 
mortality in the ADHERE trial results. This benefit is 
best seen with NT-proBNP, regarded as the best 
predictor out of all the natriuretic peptides, itself 
improving the prognostic value of MR-proANP when 
used in combination).3 Besides reducing in-patient 
mortality with relative falls in natriuretic peptide levels, 
the clinical usefulness of these proteins extends to 
outpatient mortality. The absolute NP level at discharge 
seems to have an excellent evaluation of ventricular 
function. A high level of natriuretic peptide indicates the 
absence of a complete optivolaemic status and is 
associated with a higher risk of hospitalisation after 
ADHF, particularly in the region of 600-700-pg/ml for 
BNP and >7000 pg/ml for NT-proBNP.7  
These markers are said to be the pioneers in a 
biomarker guided therapeutic approach, widely used to 
assess fluid overload in HF patients. Studies show that 
angiotensin converting enzyme inhibitors (ACEi), 
angiotensin receptor blockers (ARBs), diuretics, 
spironolactone and perhaps long term beta-blockers 
(levels increase with short term beta-blockade) actually 
decrease natriuretic peptide levels. Several small studies 
and a recent meta-analysis (Figure 2) including the 
Troughton, STARBRITE, STARS-BNP, 
BATTLESCARRED, TIME-CHF and PRIMA Trials by 
Felker et al in 2009 suggest overall improved clinical 
outcomes with a biomarker guided approach using NPs. 
That said, one should interpret results with caution as 
some of these trials had wide confidence intervals for the 
hazard ratios, most crossing the line of no effect.8 The 
on-going GUIDE-IT randomised control trial might yet 
reveal the usefulness of such an approach though at this 
point, actual data on the benefit is still lacking.9 
Knowledge of a patient's baseline peptide levels 
may further improve diagnostic accuracy, reason being 
that high levels may actually be the patient's 
optivolaemic (dry) level due to persistent myocardial 
strain, even after resolution of the acute exacerbation. In 
any case, serial levels can be very useful in both in-
patient and out-patient settings. To gain full advantage 
of their clinical applicability, the caring physician should 
aim at decreasing NP levels present during the acute 
volume overload (wet) phase down to optivolaemic (dry) 
levels.5 
 
Figure 2: Forest plot of all-cause mortality among 
patients with heart failure in biomarker guided therapy 
versus control groups in a randomized fashion8 
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Soluble ST2 (sST2) 
ST2 is part of the Interluekin-1 (IL-1) receptor 
family, the gene coding for a trans-membrane receptor 
(ST2L) and soluble form (sST2). The ligand of ST2 (IL-
33) is involved in reducing fibrosis and hypertrophy in 
mechanical strain. Studies have shown that excess sST2 
is involved in cardiac hypertrophy, fibrosis, ventricular 
dilatation and reduced ventricular contractility. 
Iatrogenic sST2 administration blocks the anti-
hypertrophic influences of IL-33 in a dose dependent 
fashion, highlighting its possible involvement in the 
pathogenesis of HF.10 
sST2 levels are higher in ADHF when compared to 
control, increasing with worsening severity and reduced 
left ventricular ejection fraction (LVEF), making it a 
useful diagnostic tool.3 Besides being associated with 
decompensation, high levels in a healthy asymptomatic 
population are also able to predict a worse 
cardiovascular morbidity. Correlation analysis in the 
Framingham heart study showed that age, sex, diabetes 
and hypertension where highly correlated with sST2 
meaning that baseline levels should be interpreted 
accordingly.10 The potential of sST2 as a predictor 
biomarker is quite significant and was found to be non-
inferior to NT-proBNP in mortality prediction. The 
majority of cardiovascular events occur when both 
biomarkers are elevated, meaning that a combination of 
ST2 and NT-proBNP might synergistically increase their 
prediction abilities. 
The potential for sST2 as a prognostic biomarker 
has been suggested after the results of the PROTECT 
study. Higher baseline sST2 values during ADHF and 
chronic HF were associated with future cardiovascular 
events (HF hospitalisation and cardiovascular death).10-11 
The PREDICT Trial also showed that sST2 is the 
strongest predictor of death at four years in patients with 
acute dyspnoea, bypassing even the NPs. High baseline 
levels of sST2 were also associated with death or new 
congestive HF in acute myocardial infarction patients in 
the TIMI-14 and ENTIRE-TIMI-23 trials, meaning that 
sST2 may one day also be used to predict heart failure 
after myocardial infarction.3  
The low intra-individual biological variation of 
sST2 compared to other cardiac biomarkers offers a 
significant advantage in its utility for serial testing, as 
acute changes in blood levels are more diagnostic.10 In a 
recently published post hoc analysis of the PROTECT 
study, Januzzi et al hypothesized the potential of sST2 in 
guiding beta blocker therapy, similar to guiding anti-HF 
treatment according to NP levels. sST2 decreases when 
maximizing beta blockade, indicating that the latter in 
some way interferes with cardiac remodelling by 
inhibiting sST2, thus improving prognosis. This tends to 
be most effective in patients with high levels of sST2 at 
baseline, possibly being of some use in a select cohort of 
heart failure patients, especially as it mimics 
decompensated states.11 
 
Galectin-3 
Galectin-3 is another promising biomarker, 
associated with the cumulative development of fibrosis 
and apoptosis in cardiac remodelling. Studies in rats 
have showed that galectin-3 is already high in those with 
compensated hypertrophy of failure prone hearts. The 
gene for galectin-3 was the strongest up-regulated gene 
in ADHF. In this same study, a pericardial infusion of 
galectin-3 in previously normal rats also induced ADHF, 
revealing it actually plays a role in the pathophysiology 
of heart failure, possibly by direct cardio-toxicity or by 
indirect acute kidney injury.12-14 
While its expression is maximal at peak fibrosis and 
virtually absent after recovery,14 there seems to be no 
promise as a diagnostic marker of HF, since its 
expression occurs way before ADHF is clinically 
evident.3 Analysis of the Framingham heart study did 
however provide conclusive evidence that galectin-3 
levels in well and asymptomatic patients in the 
community, accurately predicted an increased risk for 
future heart failure and mortality (Figure 3). Levels 
where positively associated with left ventricular mass, 
with no difference in baseline values present when 
comparing future ADHF of normal versus reduced 
LVEF.15 Results by De Boer et al (2011) who looked at 
galectin-3 levels in two equal and comparable groups of 
low or preserved LVEF HF revealed that galectin-3 
appeared to be a better prognostic marker in the latter 
group, with one hypothesizing that it plays a more 
prominent role in the pathophysiology of preserved 
LVEF.16 
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Figure 3: The cumulative incidence of heart failure (HF) increasing with higher galectin-3 quartiles15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Galectin-3 also has the potential as an important 
prognostic biomarker during admission with ADHF, 
predicting death or re-hospitalisation with ADHF after 
discharge. Plasma levels in patients presenting with 
acute dyspnoea have a higher 60 day mortality or 
recurrent admissions with HF, marginally better than 
NT-proBNP.17 Both biomarkers complement each other 
and improve mortality prediction. Higher galectin-3 
levels showed a higher four-year mortality rate in 
patients presenting with ADHF.14 According to the 
PROVE-IT-TIMI 22 study, high Galectin-3 levels in 
patients admitted with acute coronary syndrome 
predicted the onset heart failure after the index 
admission.6 As per the DEAL-HF study, its prognostic 
ability also applies to compensated HF irrespective of 
New York Heart Association (NYHA) functional class.18 
Different to other biomarkers, in-vivo studies in 
animals have shown galectin-3 to be directly involved in 
the pathophysiology of HF, precipitating ADHF when 
compensatory measures fail. It is also associated with 
inflammatory cytokines (CRP), Interleukin-6 (IL-6) and 
Vascular Endothelial Growth Factor (VEGF) in the 
overall remodelling pathway, further revealing its role in 
structural changes in the heart. Treating the cause rather 
than the effect of ADHF might someday hold promise in 
galectin-3 targeted therapies and galectin-3 can someday 
be used to risk stratifying remodelling (high-risk) versus 
non-remodelling (low-risk) ADHF. Similarly to the 
effect of sST2 with beta blockade, future research might 
develop specific galectin-3 targeted therapies which 
could hypothetically directly reverse remodelling and 
treat the cause rather than the effect.3 
 
Growth Differentiation Factor 15 (GDF-15) 
GDF-15 is a member of the transforming growth 
factor beta (TGF-β) superfamily, expressed in stressful 
situations including inflammation and remodelling, in an 
attempt to inhibit myocyte hypertrophy, apoptosis and 
adverse remodelling [2]. Levels are high in ADFH when 
compared to a control group, correlated with severity 
and reduced LVEF, just like sST2. It is particularly 
diagnostic, as seen in the study by Wang et al also 
suggesting it can help differentiate reduced from 
preserved LVEF ADHF.8 GDF-15 is however non-
specific, with high levels also present in severe liver 
disease, pregnancy and certain cancers.3 
GDF-15 can be used to help predict mortality and 
heart failure. Levels also correlate with NT-proBNP in 
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post-myocardial infarction, possibly implying that it 
might be useful to risk stratify those patients at risk of 
adverse cardiac events in the early or late stages after 
discharge.19 There are however no studies to date about 
GDF-15 serial testing and GDF-15 targeted drug 
therapies. 
 
Troponin T 
Troponin T is a regulatory protein attached to 
tropomyosin in cardiac myocytes, released in response 
to myocardial infarction secondary to coronary 
(atherosclerosis) or non-coronary causes (cytotoxicity, 
apoptosis and inflammation).3 
It is a sensitive marker of myocardial injury with 
levels correlated to the degree of myocardial necrosis, 
with high sensitivities now available detecting even 
lower levels. It is however not a specific diagnostic 
marker for ADHF with high levels also possible in acute 
kidney injury, sepsis, subarachnoid haemorrhage, 
amongst others.3 
Since elevations in Troponin levels are often 
associated with unclear therapeutic ramifications in the 
non-acute setting, they are at present not useful for risk 
stratification or prediction. However, Miller et al 
demonstrated a higher mortality risk and increased rates 
of cardiac transplantation in patients with persistently 
high levels in asymptomatic stable NYHA Class III and 
IV HF patients.20 
Troponin T is an independent prognostic predictor 
of mortality, mimicking NT-proBNP and sST2, with 
addition of both biomarkers improving prognostic 
capabilities significantly.3 There are no studies regarding 
Troponin T targeted therapies or the management 
implications of serial testing. 
 
Conclusion  
More studies are needed to fully validate 
established biomarkers for clinical practice. Better 
biomarkers are currently needed for diagnosis, screening 
and monitoring. With the integration of genomic, 
proteomic, phenotypic and transcriptional profiling, a 
new era in cardiology of ''personalized medicine' might 
at some point become a reality.9 
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